In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
As of close of business last night, Relay Therapeutics Inc’s stock clocked out at $3.52, down -3.03% from its previous closing price of $3.63. In other words, the price has decreased by -$3.03 from its previous closing price. On the day, 4.24 million shares were traded. RLAY stock price reached its highest trading level at $3.71 during the session, while it also had its lowest trading level at $3.485.
Ratios:
To gain a deeper understanding of RLAY’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 19.96 and its Current Ratio is at 19.96. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.06.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wells Fargo on April 17, 2025, initiated with a Equal Weight rating and assigned the stock a target price of $4.
On September 10, 2024, Jefferies Upgraded its rating to Buy which previously was Hold and also upped its target price recommendation from $10.60 to $16.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jul 29 ’25 when Rahmer Peter sold 15,724 shares for $3.68 per share. The transaction valued at 57,864 led to the insider holds 377,998 shares of the business.
Rahmer Peter sold 1,359 shares of RLAY for $5,083 on Jul 28 ’25. The insider now owns 393,722 shares after completing the transaction at $3.74 per share. On Jul 29 ’25, another insider, Catinazzo Thomas, who serves as the Chief Financial Officer of the company, sold 18,380 shares for $3.68 each. As a result, the insider received 67,638 and left with 335,295 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RLAY now has a Market Capitalization of 603486400 and an Enterprise Value of -59709720. For the stock, the TTM Price-to-Sale (P/S) ratio is 78.58 while its Price-to-Book (P/B) ratio in mrq is 0.83. Its current Enterprise Value per Revenue stands at -7.776 whereas that against EBITDA is 0.16.
Stock Price History:
The Beta on a monthly basis for RLAY is 1.63, which has changed by -0.53866315 over the last 52 weeks, in comparison to a change of 0.18569505 over the same period for the S&P500. Over the past 52 weeks, RLAY has reached a high of $10.72, while it has fallen to a 52-week low of $1.77. The 50-Day Moving Average of the stock is 3.92%, while the 200-Day Moving Average is calculated to be -11.56%.
Shares Statistics:
It appears that RLAY traded 2.10M shares on average per day over the past three months and 3611950 shares per day over the past ten days. A total of 170.48M shares are outstanding, with a floating share count of 129.32M. Insiders hold about 24.57% of the company’s shares, while institutions hold 82.95% stake in the company. Shares short for RLAY as of 1752537600 were 21520228 with a Short Ratio of 10.24, compared to 1749772800 on 22524543. Therefore, it implies a Short% of Shares Outstanding of 21520228 and a Short% of Float of 15.24.
